Stock CDXS CODEXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Codexis, Inc. Stock

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 09:31:36 2025-01-22 am EST 		5-day change 1st Jan Change
5.085 USD +0.69% Intraday chart for Codexis, Inc. +11.48% +5.87%
Jan. 16 Codexis, Inc. Appoints Christos Richards to Board of Directors CI
Jan. 02 Caribou Biosciences Names Sri Ryali CFO MT

Valuation: Codexis, Inc.

Capitalization 411M 395M 373M 334M 589M 35.54B 656M 4.52B 1.68B 14.64B 1.54B 1.51B 63.87B P/E ratio 2024 *
-6.36x
P/E ratio 2025 * -7.35x
Enterprise value 411M 395M 373M 334M 589M 35.54B 656M 4.52B 1.68B 14.64B 1.54B 1.51B 63.87B EV / Sales 2024 *
6.29x
EV / Sales 2025 * 6.17x
Free-Float
97.77%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Codexis, Inc.

Dynamic Chart

Latest news: Codexis, Inc.

Codexis, Inc. Appoints Christos Richards to Board of Directors Jan. 16 CI
Caribou Biosciences Names Sri Ryali CFO Jan. 02 MT
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer Jan. 02 CI
Codexis, Inc.(NasdaqGS:CDXS) added to NASDAQ Biotechnology Index Dec. 22 CI
Kairos Pharma, Ltd. Announces Board and Committee Changes Dec. 13 CI
Codexis, Inc. - Special Call Nov. 14
Codexis, Inc. Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics Nov. 14 CI
Codexis, Inc. Appoints Raymond De Vré to Board of Directors Nov. 12 CI
Earnings Flash (CDXS) CODEXIS Posts Q3 Revenue $12.8M 24-10-31 MT
Codexis, Inc., Q3 2024 Earnings Call, Oct 31, 2024 24-10-31
Codexis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 24-10-31 CI
Codexis Expands Cash Reserves by $31 Million, Creates Chief Technology Officer Role 24-10-02 MT
Codexis, Inc. Announces Executive Changes 24-10-02 CI
More news

Last Transcript: Codexis, Inc.

Logo Codexis, Inc.
Codexis, Inc. - Special Call
Nov. 14
More transcripts

Analysts' recommendations: Codexis, Inc.

Benchmark Capital Downgrades Codexis to Hold From Buy 24-08-19 MT
Cantor Fitzgerald Starts Codexis With Overweight Rating, $11 Price Target 24-05-30 MT
Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9 24-02-29 MT
Benchmark Downgrades Codexis to Hold From Buy 23-11-07 MT
Piper Sandler Trims Price Target on Codexis to $10 From $14, Maintains Overweight Rating 23-11-06 MT
More recommendations

Press Releases: Codexis, Inc.

Codexis Appoints Christos Richards to Board of Directors Jan. 16 AQ
Codexis : Corporate Presentation January 2025 Jan. 12 PU
Codexis Announces New Employment Inducement Grants Jan. 10 AQ
Codexis Announces New Employment Inducement Grants Dec. 06 AQ
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference Nov. 19 AQ
More press releases

News in other languages: Codexis, Inc.

Ausblick Nestlé: Organisches Wachstum im Q1 von 2,8 Prozent erwartet 24-04-24
Ausblick Nestlé: Organisches Wachstum von 7,3 Prozent erwartet 24-02-21
Prévisions Nestlé: croissance organique attendue à 7,3% 24-02-21
Bourse Zurich: en rouge à l'entame de la dernière semaine de l'année 23-12-27
Nestlé Health Science achète un candidat produit de Codexis 23-12-27
More news

Quotes and Performance

1 day+0.69%
1 week+11.48%
Current month+5.87%
1 month-4.36%
3 months+53.50%
6 months+42.25%
Current year+5.87%
More quotes

Course Extremes

1 week
4.76
Extreme 4.7616
5.43
1 month
4.24
Extreme 4.24
5.51
Current year
4.24
Extreme 4.24
5.51
1 year
2.53
Extreme 2.53
6.08
3 years
1.45
Extreme 1.45
22.22
5 years
1.45
Extreme 1.45
42.01
10 years
1.45
Extreme 1.45
42.01
More quotes

Managers and Directors: Codexis, Inc.

Director TitleAgeSince
Stephen Dilly CEO
 Chief Executive Officer 65 2022-08-08
Georgia Erbez DFI
 Director of Finance/CFO 58 2024-09-29
Margaret Fitzgerald CMP
 Compliance Officer 54 2022-10-31
Manager TitleAgeSince
David Smith BRD
 Director/Board Member 65 2016-02-29
Rahul Singhvi BRD
 Director/Board Member 60 2022-09-27
Stephen Dilly CHM
 Chairman 65 -
More insiders

ETFs: Codexis, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD ETF Leverage Shares 1x ARK Genomic Tracker ETP - USD
1.09% 1 M€ 0.00% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.04% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.03% 0 M€ 0.00% -
More ETFs: Codexis, Inc.

Other Biotechnology & Medical Research

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
CODEXIS, INC. Stock Codexis, Inc.
+0.69%+11.48%+87.73%-74.53%411M
LONZA GROUP AG Stock Lonza Group AG
+1.10%+6.03%+54.73%-5.78%45.41B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.26%+3.90%-4.50%-14.63%37.33B
CELLTRION, INC. Stock Celltrion, Inc.
-0.55%-2.60%+7.21%+20.02%26.53B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
-0.75%+2.41%-21.00%-18.61%16.93B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+0.88%+0.90%+68.92%+83.93%16.43B
MODERNA, INC. Stock Moderna, Inc.
+2.55%+4.15%-64.00%-77.58%13.81B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.01%+5.38%+11.99%-14.19%12.51B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
-0.75%+5.02%+17.52%+110.90%10.78B
QIAGEN N.V. Stock Qiagen N.V.
+0.28%+4.24%+2.09%-5.37%10.56B
Average +0.38%+4.30%+16.07%+0.42% 19.07B
Weighted average by Cap. +0.31%+3.63%+14.67%+3.38%
See all sector performances

Financials

2024 *2025 *
Net sales 65.29M 62.76M 59.21M 53M 93.65M 5.65B 104M 718M 266M 2.33B 245M 240M 10.15B 66.61M 64.02M 60.4M 54.07M 95.54M 5.76B 106M 733M 272M 2.37B 250M 245M 10.35B
Net income -57.59M -55.36M -52.23M -46.75M -82.61M -4.98B -91.91M -634M -235M -2.05B -216M -212M -8.95B -53.16M -51.1M -48.21M -43.15M -76.25M -4.6B -84.84M -585M -217M -1.89B -199M -195M -8.26B
Net Debt - -
More financial data * Estimated data

Company Profile

Logo Codexis, Inc.
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Employees
174
Sector
Biotechnology & Medical Research
Calendar
2025-02-25 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
25-01-21 5.050 $ +1.00% 728,970
25-01-17 5.000 $ +1.63% 638,754
25-01-16 4.920 $ +1.03% 602,631
25-01-15 4.870 $ +7.51% 813,173
25-01-14 4.530 $ +0.22% 674,181

Delayed Quote Nasdaq, January 21, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart CODEXIS-INC More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
BB
surperformance-ratings-light-chart CODEXIS-INCMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.050USD
Average target price
7.500USD
Spread / Average Target
+48.51%
Consensus
Profit revisions
estimates-change-chart CODEXIS-INC Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart CODEXIS-INC Company calendar
  1. Stock Market
  2. Equities
  3. CDXS Stock